ライフサイエンスコーパス: macroglobulinemia

1 -naive, or relapse or refractory Waldenstrom macroglobulinemia.

2 geting, such as interleukin-6 in Waldenstrom macroglobulinemia.

3 ssic Hodgkin lymphoma, and 2 had Waldenstrom macroglobulinemia.

4 ly analyzed from patients with Waldenstrom's macroglobulinemia.

5 in significance, and 1 case of Waldenstrom's macroglobulinemia.

6 yloidosis, multiple myeloma, and Waldenstrom macroglobulinemia.

7 (CLL), mantle cell lymphoma, and Waldenstrom macroglobulinemia.

8 ts with mantle cell lymphoma and Waldenstrom macroglobulinemia.

9 ations are highly prevalent in Waldenstrom's macroglobulinemia.

10 oldering plasma cell myeloma, or Waldenstrom macroglobulinemia.

11 fe in pretreated patients with Waldenstrom's macroglobulinemia.

12 hich is mutated in a fraction of Waldenstrom macroglobulinemia.

13 f acalabrutinib in patients with Waldenstrom macroglobulinemia.

14 marginal zone B-cell lymphoma or Waldenstrom macroglobulinemia.

15 observed in the pathogenesis of Waldenstrom macroglobulinemia.

16 at regulate tumor progression in Waldenstrom macroglobulinemia.

17 cytic lymphoma with or without Waldenstrom's macroglobulinemia (10).

18 th heavily pretreated MM (22) or Waldenstrom macroglobulinemia (3) were administered selinexor (3-60

19 all, and a 3-fold higher risk of Waldenstrom macroglobulinemia, a low-grade lymphoma.

20 Among the patients with Waldenstrom's macroglobulinemia, a somatic variant (T-->C) in LPL cell

21 ive therapeutic options for the treatment of macroglobulinemia, a structured approach to management o

22 es from 49 of 54 patients with Waldenstrom's macroglobulinemia and in 3 of 3 patients with non-IgM-se

23 2), previously associated with Waldenstrom's macroglobulinemia and lymphoplasmacytoid lymphoma.

24 n be useful in differentiating Waldenstrom's macroglobulinemia and non-IgM LPL from B-cell disorders

25 The records of patients with Waldenstrom macroglobulinemia and OCT documentation of serous macula

26 Two patients with Waldenstrom's macroglobulinemia and one patient with HD achieved a PR.

27 Four patients (8 eyes) with Waldenstrom macroglobulinemia and serous retinal detachment were ide

28 marginal zone lymphoma, 29 with Waldenstrom macroglobulinemia, and 57 with B-cell chronic lymphoprol

29 ign monoclonal IgM gammopathy, Waldenstrom's macroglobulinemia, and diffuse large B cell lymphoma.

30 Multiple myeloma and Waldenstrom macroglobulinemia are incurable hematologic malignancies

31 with newly diagnosed and previously treated macroglobulinemia are presented on the basis of the best

32 ll lines, as well as a CD56(-) Waldenstrom's macroglobulinemia cell line.

33 NF-kappaB nuclear staining, in Waldenstrom's macroglobulinemia cells expressing MYD88 L265P.

34 diffuse large B-cell lymphoma, Waldenstroms macroglobulinemia, chronic lymphocytic leukemia and mult

35 myeloma, IgM lymphoma, primary amyloidosis, macroglobulinemia, chronic lymphocytic leukemia, or plas

36 values for non-Hodgkin lymphoma, Waldenstrom macroglobulinemia, cryoglobulinemia, and thyroiditis wer

37 sal in multiple myeloma, whereas Waldenstrom macroglobulinemia generally does not harbor translocatio

38 malities in multiple myeloma and Waldenstrom macroglobulinemia have implications for disease progress

39 entified in 50% of patients with Waldenstrom macroglobulinemia, however.

40 andard of care for patients with Waldenstrom macroglobulinemia; however, infectious and hematologic t

41 Histologic transformation of Waldenstrom macroglobulinemia (HT-WM) carries a poor prognosis with

42 clonal IgM from a patient with Waldenstrom's macroglobulinemia hydrolyzed Abeta40 at the Lys-28-Gly-2

43 ents (relative risk [RR], 14.8), Waldenstrom macroglobulinemia in 6 (RR, 262), primary amyloidosis in

44 Waldenstrom macroglobulinemia is a distinct low-grade lymphoprolifer

45 Waldenstrom macroglobulinemia is a similar disease with secretion of

46 Waldenstrom's macroglobulinemia is an incurable, IgM-secreting lymphop

47 Inflammatory form of Waldenstrom macroglobulinemia (iWM) predicts outcomes after immuno-c

48 e 6th International Workshop for Waldenstrom Macroglobulinemia (IWWM) and the modified 3rd IWWM works

49 the International Workshop on Waldenstrom's Macroglobulinemia (IWWM).

50 ma, a myopathy associated with Waldenstrom's macroglobulinemia, Lambert-Eaton myasthenic syndrome, an

51 4.3), lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia (LPL/WM; RR = 4.0; 1.5-11), and chroni

52 large B-cell lymphoma and 90% of Waldenstrom macroglobulinemia, making it conceptually attractive to

53 ng chronic lymphocytic leukemia, Waldenstrom macroglobulinemia, mantle cell lymphoma, and marginal zo

54 eloid leukemia/myelofibrosis and Waldenstrom macroglobulinemia/myeloma.

55 non-Hodgkin lymphoma (n = 1359), Waldenstrom macroglobulinemia (n = 165), and cryoglobulinemia (n = 5

56 multiple myeloma (n = 2, 11%), Waldenstrom's macroglobulinemia (n = 2, 11%), extranodal marginal zone

57 (Richter transformation; n = 7), Waldenstrom macroglobulinemia (n = 4), and marginal zone lymphoma (n

58 %), with the most frequent being Waldenstrom macroglobulinemia (n = 9, 20%).

59 sue samples from patients with Waldenstrom's macroglobulinemia or non-IgM LPL and in B cells from hea

60 Observations: Waldenstrom macroglobulinemia remains a rare, incurable cancer, with

61 Following profiling, Waldenstrom macroglobulinemia samples clustered with chronic lymphoc

62 ng performed after separation of Waldenstrom macroglobulinemia samples into populations with plasma c

63 hology revealed that plasma cell Waldenstrom macroglobulinemia samples most closely resembled multipl

64 ival of patients with smoldering Waldenstrom macroglobulinemia (SWM).

65 ring mutation in patients with Waldenstrom's macroglobulinemia that can be useful in differentiating

66 (at least one previous therapy) Waldenstrom macroglobulinemia that required treatment, an Eastern Co

67 emic treatment of the underlying Waldenstrom macroglobulinemia, the visual prognosis was guarded.

68 -old white man with history of Waldenstrom's macroglobulinemia transforming to large B-cell lymphoma

69 iNHL (follicular, marginal zone, Waldenstrom macroglobulinemia) treated with chemotherapy from 2006 t

70 ow biopsy specimen, diagnosis of Waldenstrom macroglobulinemia was established, and computed tomograp

71 rabine in Patients With Advanced Waldenstrom Macroglobulinemia) was undertaken in 101 centers in five

72 yelokathexis (WHIM) syndrome and Waldenstrom macroglobulinemia, we demonstrated that mutant B cells e

73 which progresses to lymphoma or Waldenstrom macroglobulinemia, whereas IgA and IgG MGUS progress to

74 s from HID or individuals with Waldenstrom's macroglobulinemia who do not have joint disease.

75 n 63 symptomatic patients with Waldenstrom's macroglobulinemia who had received at least one previous

76 addition, 2 of 3 patients with Waldenstrom's macroglobulinemia who had wild-type MYD88 had somatic va

77 LPL cells in 30 patients with Waldenstrom's macroglobulinemia, with paired normal-tissue and tumor-t

78 ents with multiple myeloma and Waldenstrom's macroglobulinemia without invasive fungal disease to add

79 We included patients with Waldenstrom macroglobulinemia (WM) and a radiologic and/or cytologic

80 oliferative disorders, including Waldenstrom macroglobulinemia (WM) and chronic lymphocytic leukemia,

81 atment options for patients with Waldenstrom macroglobulinemia (WM) and closely related disorders inc

82 understanding of the biology of Waldenstrom macroglobulinemia (WM) and in therapeutic options for WM

83 e (MGUS), multiple myeloma (MM), Waldenstrom macroglobulinemia (WM) and light chain AL amyloidosis, a

84 omatic mutation in patients with Waldenstrom macroglobulinemia (WM) and provide insight into its biol

85 Familial aggregation of Waldenstrom macroglobulinemia (WM) and related B-cell disorders (BCD

86 mutation is highly prevalent in Waldenstrom macroglobulinemia (WM) and supports malignant growth thr

87 me inhibitors are effective in Waldenstrom's macroglobulinemia (WM) but require parenteral administra

88 Familial aggregation of Waldenstrom macroglobulinemia (WM) cases, and the clustering of B-ce

89 Waldenstrom macroglobulinemia (WM) cells present with increased expr

90 d to synergistic cytotoxicity in Waldenstrom macroglobulinemia (WM) cells that was mediated through a

91 on of investigational agents for Waldenstrom macroglobulinemia (WM) has been limited by the lack of i

92 M-producing gammopathies such as Waldenstrom macroglobulinemia (WM) has not been well characterized b

93 ut the molecular pathogenesis of Waldenstrom macroglobulinemia (WM) has significantly advanced, the p

94 Patients with Waldenstrom macroglobulinemia (WM) have disparate outcomes.

95 s in the blood of a patient with Waldenstrom macroglobulinemia (WM) indicates the functional importan

96 Waldenstrom macroglobulinemia (WM) is a B-cell disorder characterize

97 Waldenstrom macroglobulinemia (WM) is a B-cell malignancy characteri

98 Waldenstrom macroglobulinemia (WM) is a B-cell malignancy characteri

99 Waldenstrom macroglobulinemia (WM) is a B-cell malignancy uniquely c

100 Waldenstrom macroglobulinemia (WM) is a B-cell neoplasm manifested b

101 Waldenstrom macroglobulinemia (WM) is a distinct B-cell disorder res

102 Waldenstrom macroglobulinemia (WM) is a distinct B-cell lymphoprolif

103 Waldenstrom macroglobulinemia (WM) is a distinct B-cell lymphoprolif

104 Waldenstrom's macroglobulinemia (WM) is a distinct clinicobiological e

105 Waldenstrom macroglobulinemia (WM) is a lymphoid neoplasm characteri

106 Waldenstrom macroglobulinemia (WM) is a proliferative disorder of Ig

107 Waldenstrom macroglobulinemia (WM) is a rare, lymphoplasmacytic lymp

108 Waldenstrom's Macroglobulinemia (WM) is an IgM-secreting bone marrow (

109 Waldenstrom macroglobulinemia (WM) is an incurable low-grade B-cell

110 Waldenstrom macroglobulinemia (WM) is an incurable low-grade lymphom

111 Waldenstrom macroglobulinemia (WM) is an incurable low-grade lymphop

112 Waldenstrom macroglobulinemia (WM) is an incurable lymphoplasmacytic

113 Waldenstrom macroglobulinemia (WM) is an uncommon lymphoma character

114 Current information on Waldenstrom macroglobulinemia (WM) is based on retrospective or sing

115 Waldenstrom's macroglobulinemia (WM) is characterized by an overproduc

116 Waldenstrom macroglobulinemia (WM) is characterized by widespread in

117 Waldenstrom macroglobulinemia (WM) is preceded by asymptomatic WM (A

118 evel genetic characterization of Waldenstrom macroglobulinemia (WM) is required to improve our unders

119 sis on a series of MYD88-mutated Waldenstrom macroglobulinemia (WM) patients and identified 2 distinc

120 ide and rituximab in symptomatic Waldenstrom macroglobulinemia (WM) patients naive to either agent.

121 tivity and is present in >90% of Waldenstrom macroglobulinemia (WM) patients.

122 , the role of these molecules in Waldenstrom macroglobulinemia (WM) remains poorly understood.

123 The genetic basis for Waldenstrom macroglobulinemia (WM) remains to be clarified.

124 (71%) progressed to symptomatic Waldenstrom macroglobulinemia (WM) requiring treatment, one to prima

125 whole exome-sequencing study of Waldenstrom macroglobulinemia (WM) suggested a high frequency of MYD

126 rates and durable remissions in Waldenstrom macroglobulinemia (WM) that are impacted by MYD88 and CX

127 The survival of patients with Waldenstrom macroglobulinemia (WM) varies enormously.

128 lymphoma (ABC DLBCL) and BCWM.1 Waldenstrom macroglobulinemia (WM) xenografted mice with wild-type B

129 f IL-21 has not been examined in Waldenstrom macroglobulinemia (WM), a B-cell lymphoma characterized

130 For Waldenstrom macroglobulinemia (WM), a distinct subtype of lymphoplas

131 Waldenstrom macroglobulinemia (WM), a distinctive subtype of non-Hod

132 rmation on the cell of origin in Waldenstrom macroglobulinemia (WM), a longstanding puzzle due to con

133 riate agents in the treatment of Waldenstrom macroglobulinemia (WM), a lymphoplasmacytic lymphoma.

134 eptor type 4 (CXCR4) mutation in Waldenstrom macroglobulinemia (WM), a marker of tumor aggression and

135 Waldenstrom macroglobulinemia (WM), an IgM-associated lymphoplasmacy

136 proximately 95% of patients with Waldenstrom macroglobulinemia (WM), as well as other B-cell malignan

137 Mantle Cell Lymphoma (MCL), and Waldenstrom macroglobulinemia (WM), between 01-Jan-2008 and 31-Dec-2

138 d recurring somatic mutations in Waldenstrom macroglobulinemia (WM), including MYD88 (95%-97%), CXCR4

139 reated symptomatic patients with Waldenstrom macroglobulinemia (WM), most of which were of advanced a

140 molecular changes that occur in Waldenstrom macroglobulinemia (WM), we employed antibody-based prote

141 nd its use has been validated in Waldenstrom macroglobulinemia (WM), where bortezomib has been succes

142 l B cell malignancies, including Waldenstrom macroglobulinemia (WM), where elevated IgM is associated

143 Waldenstrom macroglobulinemia (WM), which has an immunoglobulin M (I

144 in (mTOR) complex 1 inhibitor in Waldenstrom macroglobulinemia (WM).

145 ents with symptomatic, untreated Waldenstrom macroglobulinemia (WM).

146 ing fludarabine and rituximab in Waldenstrom macroglobulinemia (WM).

147 s an important therapeutic for Waldenstrom's macroglobulinemia (WM).

148 gnant lymphoplasmacytic cells in Waldenstrom macroglobulinemia (WM).

149 has not yet been investigated in Waldenstrom macroglobulinemia (WM).

150 d recurring somatic mutations in Waldenstrom macroglobulinemia (WM).

151 nd CXCR4 mutations are common in Waldenstrom macroglobulinemia (WM).

152 nd CXCR4 (30%-40%) are common in Waldenstrom macroglobulinemia (WM).

153 a cornerstone of treatment for Waldenstrom's macroglobulinemia (WM).

154 cacy of ibrutinib-rituximab in Waldenstrom's macroglobulinemia (WM).

155 atologic malignancies, including Waldenstrom macroglobulinemia (WM).

156 ersus ibrutinib in patients with Waldenstrom macroglobulinemia (WM).

157 ding MYD88, CXCR4, and ARID1A in Waldenstrom macroglobulinemia (WM).

158 lls derived from patients with Waldenstrom's macroglobulinemia (WM).

159 peripheral neuropathy (PN) in Waldenstrom's macroglobulinemia (WM).

160 eport its aberrant activation in Waldenstrom macroglobulinemia (WM).

161 cal presentation and survival in Waldenstrom macroglobulinemia (WM).

162 ns in MYD88 (L265P) and CXCR4 in Waldenstrom macroglobulinemia (WM).

163 tment approach for patients with Waldenstrom macroglobulinemia (WM).

164 reated symptomatic patients with Waldenstrom macroglobulinemia (WM).

165 atients with relapsed/refractory Waldenstrom macroglobulinemia (WM).

166 recurring somatic mutation in Waldenstrom's macroglobulinemia (WM).

167 previously treated patients with Waldenstrom macroglobulinemia (WM).

168 me is described in patients with Waldenstrom macroglobulinemia (WM).

169 a (LPL), including IgM-secreting Waldenstrom macroglobulinemia (WM).

170 atients with relapsed/refractory Waldenstrom macroglobulinemia (WM).

171 atients with relapsed/refractory Waldenstrom macroglobulinemia (WM).

172 ance (IgM-MGUS) and asymptomatic Waldenstrom macroglobulinemia (WM; aWM) are precursor conditions of

173 ), multiple myelomas (MM), and Waldenstrom's macroglobulinemias (WM) using protein macroarrays that w

174 mphocytic lymphomas (SLL), two Waldenstrom's macroglobulinemias (WM), and one marginal zone lymphoma.

175 with lymphoplasmacytic lymphoma (Waldenstrom macroglobulinemia [WM]), being either absent or present

176 ing data in 34 subjects (23 with Waldenstrom macroglobulinemia [WM], 6 with IgM monoclonal gammopathy